Specific IgG Response Against Mycobacterium Avium Paratuberculosis in Children and Adults with Crohn's Disease

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 May 10

PMID 23658774

Citations 6

Authors

Julien Verdier

Louis Deroche

Matthieu Allez

Caroline Loy

Franck Biet

Christelle C Bodier

Sylvie Bay

Christelle Ganneau

Tamara Matysiak-Budnik

Jean Marc Reyrat

Martine Heyman

Nadine Cerf-Bensussan

Frank M Ruemmele

Sandrine Menard

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Presence of serum antibodies against Mycobacterium avium paratuberculosis (MAP) in Crohn's Disease (CD) as a disease characteristic remains controversial. In the present work, we assessed antibody reactivity of serum and intestinal fluid against four distinct MAP-antigens, including the recently identified MAP-specific lipopentapeptide (L5P).

Methods: Immunoglobulin concentrations and specificity against 3 non MAP-specific antigens: glycosyl-transferase-d (GSD), purified protein derivative from MAP (Johnin-PPD), heparin binding haemagglutinin (MAP-HBHA) and one MAP-specific antigen: synthetic L5P were determined by ELISA in gut lavage fluids from adult controls or patients with CD, and in sera of children or adult controls or patients with CD, ulcerative colitis or celiac disease.

Results: Total IgA and IgG concentrations were increased in sera of children with CD but were decreased in sera of adults with CD, thereof specificity against MAP antigens was assessed by normalizing immunoglobulin concentrations between samples. In CD patients, IgG reactivity was increased against the four MAP antigens, including L5P in gut lavage fluids but it was only increased against L5P in sera. By contrast, anti-L5P IgG were not increased in patients with ulcerative colitis or celiac disease.

Conclusions: A significant increase in anti-L5P IgG is observed in sera of children and adults with CD but not in patients with other intestinal inflammatory diseases. Anti-L5P antibodies may serve as serological marker for CD.

Citing Articles

Engineering Synthetic Lipopeptide Antigen for Specific Detection of subsp. Infection.

Bay S, Begg D, Ganneau C, Branger M, Cochard T, Bannantine J Front Vet Sci. 2021; 8:637841.

PMID: 33969035 PMC: 8103206. DOI: 10.3389/fvets.2021.637841.

Gut dysbiosis and impairment of immune system homeostasis in perinatally-exposed mice to Bisphenol A precede obese phenotype development.

Malaise Y, Menard S, Cartier C, Gaultier E, Lasserre F, Lencina C Sci Rep. 2017; 7(1):14472.

PMID: 29101397 PMC: 5670173. DOI: 10.1038/s41598-017-15196-w.

Altered humoral immunity to mycobacterial antigens in Japanese patients affected by inflammatory demyelinating diseases of the central nervous system.

Cossu D, Yokoyama K, Tomizawa Y, Momotani E, Hattori N Sci Rep. 2017; 7(1):3179.

PMID: 28600575 PMC: 5466620. DOI: 10.1038/s41598-017-03370-z.

Seroreactivity against Specific L5P Antigen from Mycobacterium avium subsp. paratuberculosis in Children at Risk for T1D.

Niegowska M, Rapini N, Biet F, Piccinini S, Bay S, Lidano R PLoS One. 2016; 11(6):e0157962.

PMID: 27336739 PMC: 4919038. DOI: 10.1371/journal.pone.0157962.

The zoonotic potential of Mycobacterium avium ssp. paratuberculosis: a systematic review and meta-analyses of the evidence.

Waddell L, Rajic A, Stark K, McEwen S Epidemiol Infect. 2015; 143(15):3135-57.

PMID: 25989710 PMC: 9150950. DOI: 10.1017/S095026881500076X.

References

Ruemmele F . Pediatric inflammatory bowel diseases: coming of age. Curr Opin Gastroenterol. 2010; 26(4):332-6. DOI: 10.1097/MOG.0b013e328339ec2d. View

Macpherson A, Uhr T . Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science. 2004; 303(5664):1662-5. DOI: 10.1126/science.1091334. View

Pethe K, Aumercier M, Fort E, Gatot C, Locht C, Menozzi F . Characterization of the heparin-binding site of the mycobacterial heparin-binding hemagglutinin adhesin. J Biol Chem. 2000; 275(19):14273-80. DOI: 10.1074/jbc.275.19.14273. View

Benjamin R, Debanne S, Ma Y, Daniel T . Evaluation of mycobacterial antigens in an enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of tuberculosis. J Med Microbiol. 1984; 18(3):309-18. DOI: 10.1099/00222615-18-3-309. View

Polymeros D, Bogdanos D, Day R, Arioli D, Vergani D, Forbes A . Does cross-reactivity between mycobacterium avium paratuberculosis and human intestinal antigens characterize Crohn's disease?. Gastroenterology. 2006; 131(1):85-96. DOI: 10.1053/j.gastro.2006.04.021. View

Kitada S, Maekura R, Toyoshima N, Fujiwara N, Yano I, Ogura T . Serodiagnosis of pulmonary disease due to Mycobacterium avium complex with an enzyme immunoassay that uses a mixture of glycopeptidolipid antigens. Clin Infect Dis. 2002; 35(11):1328-35. DOI: 10.1086/344277. View

Jostins L, Ripke S, Weersma R, Duerr R, McGovern D, Hui K . Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491(7422):119-24. PMC: 3491803. DOI: 10.1038/nature11582. View

Nell S, Suerbaum S, Josenhans C . The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. Nat Rev Microbiol. 2010; 8(8):564-77. DOI: 10.1038/nrmicro2403. View

Koets A, Rutten V, de Boer M, Bakker D, Valentin-Weigand P, van Eden W . Differential changes in heat shock protein-, lipoarabinomannan-, and purified protein derivative-specific immunoglobulin G1 and G2 isotype responses during bovine Mycobacterium avium subsp. paratuberculosis infection. Infect Immun. 2001; 69(3):1492-8. PMC: 98047. DOI: 10.1128/IAI.69.3.1492-1498.2001. View

10.

Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M . The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis. 2010; 4(1):7-27. DOI: 10.1016/j.crohns.2009.12.003. View

11.

Momotani E, Romona N, Yoshihara K, Momotani Y, Hori M, Ozaki H . Molecular pathogenesis of bovine paratuberculosis and human inflammatory bowel diseases. Vet Immunol Immunopathol. 2012; 148(1-2):55-68. DOI: 10.1016/j.vetimm.2012.03.005. View

12.

Muller S, Schaffer T, Schoepfer A, Hilty A, Bodmer T, Seibold F . Partial overlap of anti-mycobacterial, and anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease. World J Gastroenterol. 2008; 14(23):3650-61. PMC: 2719228. DOI: 10.3748/wjg.14.3650. View

13.

Behr M, Kapur V . The evidence for Mycobacterium paratuberculosis in Crohn's disease. Curr Opin Gastroenterol. 2007; 24(1):17-21. DOI: 10.1097/MOG.0b013e3282f1dcc4. View

14.

Eckstein T, Chandrasekaran S, Mahapatra S, McNeil M, Chatterjee D, Rithner C . A major cell wall lipopeptide of Mycobacterium avium subspecies paratuberculosis. J Biol Chem. 2005; 281(8):5209-15. DOI: 10.1074/jbc.M512465200. View

15.

Brandtzaeg P, Halstensen T, Kett K, Krajci P, Kvale D, Rognum T . Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes. Gastroenterology. 1989; 97(6):1562-84. DOI: 10.1016/0016-5085(89)90406-x. View

16.

Peyrin-Biroulet L, Standaert-Vitse A, Branche J, Chamaillard M . IBD serological panels: facts and perspectives. Inflamm Bowel Dis. 2007; 13(12):1561-6. DOI: 10.1002/ibd.20226. View

17.

Travis S, Stange E, Lemann M, Oresland T, Bemelman W, Chowers Y . European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis. 2010; 2(1):24-62. DOI: 10.1016/j.crohns.2007.11.002. View

18.

Tizard M, Bull T, Millar D, Doran T, Martin H, Sumar N . A low G+C content genetic island in Mycobacterium avium subsp. paratuberculosis and M. avium subsp. silvaticum with homologous genes in Mycobacterium tuberculosis. Microbiology (Reading). 1999; 144 ( Pt 12):3413-3423. DOI: 10.1099/00221287-144-12-3413. View

19.

Chiodini R . Crohn's disease and the mycobacterioses: a review and comparison of two disease entities. Clin Microbiol Rev. 1989; 2(1):90-117. PMC: 358101. DOI: 10.1128/CMR.2.1.90. View

20.

Greenstein R . Is Crohn's disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne's disease. Lancet Infect Dis. 2003; 3(8):507-14. DOI: 10.1016/s1473-3099(03)00724-2. View